Hospitalizations due to acute heart failure represent a growing healthcare problem and a large economic burden. Iron deficiency, irrespective of anemia, is prevalent among this population and is associated with a high risk for increased mortality and rehospitalization. Tune in to discover the latest data from the AFFIRM-AHF trial. What does this new information reveal about treatment with intravenous iron in patients with acute heart failure?